Market access
By
Most-Favored-Nation Pricing: How U.S. Drug Prices Are Being Reset
A quick-read guide to the Trump administration’s MFN pricing policy and what it means for biopharma GLOBAL BIOPHARMA…
Inside Medicare’s First Price Cuts: What a 38–79% Discount on 10 Blockbuster Drugs Means for Biopharma’s Next Decade
A data-driven look at the first round of Medicare drug price negotiation, how it compares to the pricing…
How Will Emerging Drug Pricing Policies Reshape the Global Biopharma Industry in the Near and Long Term?
The global biopharmaceutical industry is entering a new policy-driven era as governments intensify efforts to control drug costs,…
Merck and Moderna’s Melanoma Vaccine Win Could Be the Proof Point mRNA Oncology Has Been Waiting For
What the Phase 3 intismeran autogene + Keytruda results mean for the next wave of personalized cancer vaccines…
The FDA Just Created a Reimbursement Pathway for AI-Driven Care — Here’s Why That Matters More Than the Device, Dexcom the first participant in its TEMPO pilot.
Analysis of the FDA’s TEMPO pilot, its first AI-enabled participant, and what it signals for how algorithmic health…
